<DOC>
	<DOCNO>NCT01179490</DOCNO>
	<brief_summary>The study objective study determine effect , safety , pharmacokinetics bendamustine multiple myeloma regimen bendamustine prednisolone .</brief_summary>
	<brief_title>Efficacy Safety Study SyB L-0501 Patients With Multiple Myeloma</brief_title>
	<detailed_description>The study objective study determine effect , safety , pharmacokinetics bendamustine untreated maladjustment hematopoietic stem cell transplantation ( HSCT ) multiple myeloma regimen bendamustine prednisolone .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients include study follow criterion meet : Patients confirm multiple myeloma ( symptomatic myeloma ) define diagnostic criterion International Myeloma Working Group ( IMWG ) . Patients measurable lesion Patients history treatment ( history chemotherapy radiotherapy ) Patients consider candidate high dose therapy/autologous stem cell transplantation due coexistent medical condition , advanced age , poor performance status , refusal high dose chemotherapy , reason judge patient and/or physician . Expected survival least 3 month Patients age 20 79 year ( time provisional registration ) Performance status ( P.S . ) grade 02 . P.S . 3 possible osteolytic lesion Patients adequately maintain organ function ( e.g. , bone marrow , heart , lung , liver , kidney , ) Patients write consent participate study obtain . Patients exclude participate study 1 follow criterion meet : Patients apparent infection ( include viral infection ) Patients serious complication ( hepatic failure , renal failure , diabetes insulin administration ) Patients complication medical history serious cardiac disease ( e.g. , myocardial infarction , ischemic heart disease ) within 2 year preliminary registration . Patients arrhythmia require treatment . Patients serious gastrointestinal symptom ( profound serious nausea / vomit diarrhea , etc . ) Patients hepatitis B virus antigen ( HBsAG ) positive , hepatitis C virus ( HCV ) antibodypositive human immunodeficiency virus ( HIV ) antibodypositive Patients serious bleed tendency [ e.g. , Disseminated intravascular coagulation ( DIC ) ] Patients interstitial pneumonia , pulmonary fibrosis pulmonary emphysema require treatment , disease past Patients apparent amyloidosis complication Patients clinical symptom invasion suspect invasion central nervous system . Patients active multiple cancer Patients previously autoimmune hemolytic anemia . Patients administer investigational drug past Patients receive hematopoietic stem cell transplantation past . Patients receive cytokine granulocyte colony stimulate factor ( GCSF ) erythropoietin blood transfusion within 1 week screen examination prior preliminary registration study Patients administer investigational drug clinical study unapproved drug within 3 month prior preliminary registration study Patients prior allergy medication similar investigational drug ( e.g. , alkylating agent , purine nucleotide analog ) , mannitol prednisolone Patients drug addiction , narcotic addiction alcoholism . Patients pregnant , breastfeed woman possibility pregnant Patients agree contraception follow period . For male , 6 month completion administration investigational drug . For female , 3 month completion administration investigational drug Patients investigator subinvestigators consider inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>